CD8A and cancer: Anti-CTLA-4 mAbs have been extensively studied in mouse models of cancer, where rejection of established tumors relies upon the impact of anti-CTLA-4 on CD4+ and CD8+ Teff and on CD4+FoxP3+ Treg cells (Peggs et al., 2009).